Milestone Pharmaceuticals (MIST) Net Cash Flow (2018 - 2026)

Milestone Pharmaceuticals' Net Cash Flow history runs 9 years deep, the most recent figure standing at -$1.7 million for Q1 2026.

• Quarterly Net Cash Flow fell 108.75% year-over-year to -$1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.2 million (down 24.95% YoY) and the FY2025 annual result came in at $47.7 million, up 313.12% from the prior year.
• Net Cash Flow was -$1.7 million for Q1 2026 at Milestone Pharmaceuticals, down from $26.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $66.3 million in Q1 2023 and bottomed at -$41.4 million in Q2 2023.
• A 5-year average of -$2.5 million and a median of -$1.7 million in 2026 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow sank 4755.88% — and 2025, when it soared 1004.1%.
• Milestone Pharmaceuticals' Net Cash Flow stood at -$29.6 million in 2022, then soared by 113.09% to $3.9 million in 2023, then soared by 222.47% to $12.5 million in 2024, then soared by 110.64% to $26.4 million in 2025, then tumbled by 106.56% to -$1.7 million in 2026.
• Business Quant data shows MIST's Net Cash Flow at -$1.7 million in Q1 2026, $26.4 million in Q4 2025, and $4.2 million in Q3 2025.